- In a wide-ranging interview on MoneyTV, Warren Wang discussed long-term goals of CIIX, including an acquisition target
- Wang sees possibility of CIIX reaching $6 to $10 million in annual volume and uplisting to the NYSE or Nasdaq
- Wang previously announced plans to spin off wholly owned subsidiary CBD Biotech with a possible Nasdaq IPO
In an interview on MoneyTV with Donald Baillargeon, ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang noted his intention, within three to five years, for the company to uplist to the New York Stock Exchange or Nasdaq Small Cap Market as it reaches up to $10 million in annual volume (http://ibn.fm/VUk14).
“I’m pretty confident that we will see profitability and revenue growth in the next three to five years,” Wang said in the interview. “Our other goal is uplisting to the New York Stock Exchange (NYSE) or to Nasdaq because we are looking at an acquisition, and we are looking for revenue of $6 to $10 million in the next three to five years. I think we will definitely qualify for NYSE or Nasdaq on the small cap side.”
A diverse company with its U.S. base located in San Gabriel, California, CIIX has built an impressive international Chinese-speaking audience for its educational programs on investing and also for its industrial, hemp-infused consumer product line. The company recently announced that it plans to spin off its wholly owned subsidiary, CBD Biotech, with a possible Nasdaq IPO. Timing would be late in FY2019 or early the following year, Wang said (http://ibn.fm/NovlI).
To that end, CIIX has moved to rebrand and unify its ChineseHempOil.com consumer product line under the new ‘opt’ brand. The move consolidates CIIX’s domestic industrial hemp-infused consumer products and features two lines: opt Hemp and opt2mist (http://ibn.fm/JDmNN).
For more information, visit the company’s website at www.ChineseInvestors.com
